BR9712988A - Imunoterapia do câncer usando células tumorais combinadas com mistura de linfócitos - Google Patents
Imunoterapia do câncer usando células tumorais combinadas com mistura de linfócitosInfo
- Publication number
- BR9712988A BR9712988A BR9712988-7A BR9712988A BR9712988A BR 9712988 A BR9712988 A BR 9712988A BR 9712988 A BR9712988 A BR 9712988A BR 9712988 A BR9712988 A BR 9712988A
- Authority
- BR
- Brazil
- Prior art keywords
- tumor
- lymphocytes
- cancer immunotherapy
- patient
- stimulated
- Prior art date
Links
- 210000004698 lymphocyte Anatomy 0.000 title abstract 5
- 210000004881 tumor cell Anatomy 0.000 title abstract 4
- 238000002619 cancer immunotherapy Methods 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 6
- 239000000427 antigen Substances 0.000 abstract 4
- 102000036639 antigens Human genes 0.000 abstract 4
- 108091007433 antigens Proteins 0.000 abstract 4
- 230000000735 allogeneic effect Effects 0.000 abstract 3
- 230000005975 antitumor immune response Effects 0.000 abstract 1
- 229940030156 cell vaccine Drugs 0.000 abstract 1
- 230000001413 cellular effect Effects 0.000 abstract 1
- 238000012258 culturing Methods 0.000 abstract 1
- 239000000284 extract Substances 0.000 abstract 1
- 210000000987 immune system Anatomy 0.000 abstract 1
- 210000000265 leukocyte Anatomy 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000004044 response Effects 0.000 abstract 1
- 230000000638 stimulation Effects 0.000 abstract 1
- 230000009885 systemic effect Effects 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/26—Universal/off- the- shelf cellular immunotherapy; Allogenic cells or means to avoid rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/47—Brain; Nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/49—Breast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/13—Tumour cells, irrespective of tissue of origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Cell Biology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Developmental Biology & Embryology (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hospice & Palliative Care (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Physiology (AREA)
- Hematology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Patente de Invenção: <B>"IMUNOTERAPIA DE CâNCER USANDO CéLULAS DE TUMOR COMBINADAS COM LINFóCITOS MISTOS"<D>. Essa invenção compreende vacinas celulares e processos de usá-las em imunoterapia de câncer, particularmente em seres humanos. As vacinas compreendem linfócitos estimulados alogênicos ao paciente sendo tratado, em conjunto com uma fonte de antígeno associado a tumor. Os linfócitos alogênicos podem ser estimulados por combinação ou co-cultivo dos mesmos com leucócitos obtidos a partir do paciente sendo tratado ou a partir de outro terceiro doador. Antígeno de tumor pode ser fornecido na forma de células de tumor primárias, linhagens de células de tumor ou extratos de tumor preparados a partir do paciente. Linfócitos alogênicos estimulados e antígeno de tumor são combinados e administrados em um local distante do tumor primário, a fim de iniciar ou intensificar uma resposta imune anti-tumor celular sistêmica. Essa abordagem supera a natureza refratária natural do sistema imune à estimulação por antígenos de tumor, gerando uma resposta de hospedeiro e aperfeiçoando potencialmente o resultado clínico.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US2854896P | 1996-10-11 | 1996-10-11 | |
PCT/US1997/018718 WO1998016238A2 (en) | 1996-10-11 | 1997-10-10 | Cancer immunotherapy using tumor cells combined with mixed lymphocytes |
Publications (1)
Publication Number | Publication Date |
---|---|
BR9712988A true BR9712988A (pt) | 2000-10-24 |
Family
ID=21844058
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR9712988-7A BR9712988A (pt) | 1996-10-11 | 1997-10-10 | Imunoterapia do câncer usando células tumorais combinadas com mistura de linfócitos |
Country Status (13)
Country | Link |
---|---|
US (1) | US6207147B1 (pt) |
EP (1) | EP0930887B1 (pt) |
JP (1) | JP2001509135A (pt) |
KR (1) | KR20000049096A (pt) |
CN (1) | CN1237909A (pt) |
AR (1) | AR004445A1 (pt) |
AT (1) | ATE229810T1 (pt) |
AU (1) | AU743855B2 (pt) |
BR (1) | BR9712988A (pt) |
CA (1) | CA2267157C (pt) |
DE (1) | DE69718029T2 (pt) |
NO (1) | NO991691L (pt) |
WO (1) | WO1998016238A2 (pt) |
Families Citing this family (90)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080220025A1 (en) * | 1995-03-17 | 2008-09-11 | James Thompson | Treating Tumors Using Implants Comprising Combinations of Allogeneic Cells |
US6203787B1 (en) | 1997-10-10 | 2001-03-20 | The Regents Of The University Of California | Treating tumors using implants comprising combinations of allogeneic cells |
US6368593B1 (en) | 1997-10-10 | 2002-04-09 | The Regents Of The University Of California | Enhanced immunogenic cell populations prepared using H2 receptor antagonists |
US7361332B2 (en) | 1995-03-17 | 2008-04-22 | The Regents Of The University Of California | Treating tumors using implants comprising combinations of allogeneic cells |
AU7154598A (en) * | 1997-04-23 | 1998-11-13 | Regents Of The University Of California, The | A cell strain with activated anti-cancer cytotoxic activity |
CA2346735C (en) | 1997-10-10 | 2005-01-25 | Meyer Pharmaceuticals, Llc | Cancer immunotherapy using allostimulated cells in a multiple sequential implantation strategy |
JP4389039B2 (ja) * | 1998-04-09 | 2009-12-24 | 株式会社リンフォテック | アロジェニックな活性化cd4陽性細胞を主成分とする医薬組成物、およびその製造方法、ならびに該医薬組成物調製用キット |
US7666609B1 (en) | 1998-12-01 | 2010-02-23 | Shanghai Cp Guojian Pharmaceutical Co. Ltd. | Method and composition for diagnosis of melanocytic lesions |
ATE407695T1 (de) * | 1999-02-09 | 2008-09-15 | Riken | Tumorimpfstoff |
ATE507285T1 (de) | 2000-04-01 | 2011-05-15 | Onyvax Ltd | Prostata zellinien und deren verwendung |
US8044259B2 (en) | 2000-08-03 | 2011-10-25 | The Regents Of The University Of Michigan | Determining the capability of a test compound to affect solid tumor stem cells |
US20080194022A1 (en) * | 2000-08-03 | 2008-08-14 | Clarke Michael F | Isolation and use of solid tumor stem cells |
US6984522B2 (en) | 2000-08-03 | 2006-01-10 | Regents Of The University Of Michigan | Isolation and use of solid tumor stem cells |
DE10043437A1 (de) * | 2000-09-04 | 2002-03-28 | Horst Lindhofer | Verwendung von trifunktionellen bispezifischen und trispezifischen Antikörpern zur Behandlung von malignem Aszites |
US7723111B2 (en) * | 2001-03-09 | 2010-05-25 | The United States Of America As Represented By The Department Of Health And Human Services | Activated dual specificity lymphocytes and their methods of use |
CA2442648C (en) | 2001-05-11 | 2012-10-16 | Pro-Virus, Inc. | Oncolytic virus therapy |
US7658926B2 (en) * | 2001-09-14 | 2010-02-09 | Opexa Pharmaceuticals, Inc. | Autologous T-cell vaccines materials and methods |
EP1293205A1 (en) * | 2001-09-18 | 2003-03-19 | G2M Cancer Drugs AG | Valproic acid and derivatives thereof for the combination therapy of human cancers, for the treatment of tumour metastasis and minimal residual disease |
AU2002365538A1 (en) * | 2001-11-27 | 2003-06-10 | Nexyte Ab | Production of eukaryotic proteins and nucleic acid molecules in c. elegans |
KR20020060643A (ko) * | 2002-06-04 | 2002-07-18 | 김진경 | 타인의 면역시스템을 이용하는 암의 치료 방법 |
PT2363710E (pt) * | 2002-08-08 | 2015-10-01 | Baylor College Medicine | Isolamento e identificação de células t |
US7571817B2 (en) * | 2002-11-06 | 2009-08-11 | Varco I/P, Inc. | Automatic separator or shaker with electromagnetic vibrator apparatus |
WO2004075855A2 (en) | 2003-02-26 | 2004-09-10 | Biomed Solutions, Llc | Process for in vivo treatment of specific biological targets in bodily fluid |
WO2004096244A1 (en) * | 2003-05-02 | 2004-11-11 | Md Bioalpha Co. Ltd. | Method of preparing tumor vaccine for the inducement of anti-tumor activity and a pharmaceutical composition containing the same |
DE602004011061T2 (de) | 2003-06-11 | 2008-11-06 | The University Of Chicago, Chicago | Erhöhte t-zell tumor-eindringung durch light- mutanten |
US7811983B2 (en) * | 2003-06-11 | 2010-10-12 | The University Of Chicago | Increased T-cell tumor infiltration and eradication of metastases by mutant light |
US20050019336A1 (en) | 2003-07-23 | 2005-01-27 | Dalgleish Angus George | Human prostate cell lines in cancer treatment |
US7696322B2 (en) * | 2003-07-28 | 2010-04-13 | Catalent Pharma Solutions, Inc. | Fusion antibodies |
EP1678295B1 (en) * | 2003-10-08 | 2013-03-06 | Vet-Stem Inc | Methods of preparing and using stem cell compositions and kits comprising the same |
US8029454B2 (en) | 2003-11-05 | 2011-10-04 | Baxter International Inc. | High convection home hemodialysis/hemofiltration and sorbent system |
US20050112684A1 (en) * | 2003-11-21 | 2005-05-26 | Eric Holzle | Class I and Class II MHC Profiling for Social and Sexual Matching of Human Partners |
EP2369014A1 (en) | 2004-02-03 | 2011-09-28 | The Regents Of The University Of Michigan Office Of Technology Transfer | Compositions and methods for characterizing, regulating, diagnosing and treating cancer |
US7858323B2 (en) | 2004-06-09 | 2010-12-28 | The Regents Of The University Of Michigan | Phage microarray profiling of the humoral response to disease |
US8257715B1 (en) | 2004-08-26 | 2012-09-04 | University Of Notre Dame | Tissue vaccines and uses thereof |
US9155789B2 (en) * | 2005-04-25 | 2015-10-13 | New York University | Use of allogenic or syngenic major histocompatibility complex (MHC) molecules as universal adjuvants for vaccines against neoplastic disease, infection and autoimmune disease |
US20090162405A1 (en) * | 2006-12-14 | 2009-06-25 | Yong Qian | Proteinase-engineered cancer vaccine induces immune responses to prevent cancer and to systemically kill cancer cells |
US9308252B2 (en) * | 2005-10-27 | 2016-04-12 | Cook Biotech, Inc. | Extracellular matrix materials as vaccine adjuvants for diseases associated with infectious pathogens or toxins |
US8778360B2 (en) * | 2005-10-27 | 2014-07-15 | University Of Notre Dame | Extracellular matrix cancer vaccine adjuvant |
US8778362B2 (en) | 2005-10-27 | 2014-07-15 | University Of Notre Dame | Anti-tumor/cancer heterologous acellular collagenous preparations and uses thereof |
US8802113B2 (en) * | 2005-10-27 | 2014-08-12 | University Of Notre Dame | Extracellular matrix cancer vaccine adjuvant |
US7723477B2 (en) | 2005-10-31 | 2010-05-25 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth |
EP1961065A4 (en) | 2005-10-31 | 2009-11-11 | Oncomed Pharm Inc | COMPOSITIONS AND METHOD FOR DIAGNOSIS AND TREATMENT OF CANCER |
JP5129149B2 (ja) * | 2005-10-31 | 2013-01-23 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | 癌を処置および診断するための組成物および方法 |
US20070243192A1 (en) * | 2006-02-21 | 2007-10-18 | Regents Of The University Of Michigan | Growth hormone receptor antagonist cancer treatment |
WO2008121102A2 (en) * | 2006-02-21 | 2008-10-09 | The Regents Of The University Of Michigan | Hedgehog signaling pathway antagonist cancer treatment |
EP2420833B1 (en) * | 2006-05-05 | 2015-09-02 | Opexa Therapeutics | T-cell vaccine |
EP2054444B1 (en) | 2006-08-04 | 2016-11-02 | MedImmune Limited | Antibodies to erbb2 |
US7972594B2 (en) * | 2006-11-13 | 2011-07-05 | Immunovative Therapies Ltd. | Ablative immunotherapy |
CN101626781B (zh) * | 2006-11-22 | 2011-10-12 | 刘华 | 制备具有抗肿瘤免疫应答反应的细胞群的方法 |
US20080147007A1 (en) * | 2006-12-19 | 2008-06-19 | Toby Freyman | Delivery device with pressure control |
EP2106439B1 (en) | 2007-01-24 | 2014-11-12 | The Regents of the University of Michigan | Compositions and methods for treating and diagnosing pancreatic cancer |
CA2676143A1 (en) * | 2007-01-26 | 2008-07-31 | University Of Louisville Research Foundation, Inc. | Modification of exosomal components for use as a vaccine |
WO2008098183A2 (en) * | 2007-02-08 | 2008-08-14 | The University Of Chicago | Combination therapy for treating cancer |
WO2008144029A1 (en) | 2007-05-14 | 2008-11-27 | The University Of Chicago | Antibody-light fusion products for cancer therapeutics |
WO2009034574A2 (en) | 2007-09-12 | 2009-03-19 | Yeda Research And Development Co. Ltd. | Methods of treating tumors in immune-privileged sites |
US8114276B2 (en) | 2007-10-24 | 2012-02-14 | Baxter International Inc. | Personal hemodialysis system |
US9283266B2 (en) * | 2008-02-28 | 2016-03-15 | University Of Notre Dame | Metastasis inhibition preparations and methods |
NZ592338A (en) | 2008-09-26 | 2012-11-30 | Oncomed Pharm Inc | Frizzled-binding agents and uses thereof |
EP2362783A2 (en) * | 2008-10-31 | 2011-09-07 | Biogen Idec MA Inc. | Light targeting molecules and uses thereof |
LT2356462T (lt) | 2008-11-11 | 2017-03-10 | The Regents Of The University Of Michigan | Anti-cxcr1 kompozicijos ir būdai |
CU23740A1 (es) * | 2009-09-29 | 2011-12-28 | Ct Ingenieria Genetica Biotech | Método de obtención de una formulación de antígenos del virus de la hepatitis b |
CN102597222B (zh) * | 2009-10-27 | 2015-07-15 | 因缪尼卡姆股份公司 | 用于增殖抗原特异性t细胞的方法 |
EP2510084B1 (en) * | 2009-12-08 | 2020-02-05 | The Board of Trustees of the University of Illionis | Stem cell immune modulation methods of use and apparatus |
US8846059B2 (en) | 2009-12-08 | 2014-09-30 | University Of Notre Dame | Extracellular matrix adjuvant and methods for prevention and/or inhibition of ovarian tumors and ovarian cancer |
US20110150934A1 (en) * | 2009-12-18 | 2011-06-23 | University Of Notre Dame | Ovarian Tumor Tissue Cell Preparations/Vaccines for the Treatment/Inhibition of Ovarian Tumors and Ovarian Cancer |
TWI535445B (zh) | 2010-01-12 | 2016-06-01 | 安可美德藥物股份有限公司 | Wnt拮抗劑及治療和篩選方法 |
WO2011116209A2 (en) * | 2010-03-17 | 2011-09-22 | The Regents Of The University Of Michigan | Using phage epitopes to profile the immune response |
CA2794674A1 (en) | 2010-04-01 | 2011-10-06 | Oncomed Pharmaceuticals, Inc. | Frizzled-binding agents and uses thereof |
KR20130055591A (ko) * | 2010-04-13 | 2013-05-28 | 가부시키가이샤 르네상스 에너지 인베스트먼트 | 암 조직 유래 세포괴 또는 암 세포 응집괴로부터 얻어지는 암 치료용 조성물과 그것을 이용한 면역요법제의 제조 방법 및 면역요법 효과 평가 방법 |
KR102229108B1 (ko) | 2011-05-03 | 2021-03-18 | 이뮤노베이티브 테라피스, 엘티디. | 생세포를 포함하는 생물학적 약물을 처리하기 위한 방법 |
HUE062102T2 (hu) * | 2011-05-24 | 2023-09-28 | BioNTech SE | Individualizált vakcinák a rák ellen |
WO2013090293A1 (en) | 2011-12-15 | 2013-06-20 | The University Of Chicago | Methods and compositions for cancer therapy using mutant light molecules with increased affinity to receptors |
WO2014066328A1 (en) | 2012-10-23 | 2014-05-01 | Oncomed Pharmaceuticals, Inc. | Methods of treating neuroendocrine tumors using wnt pathway-binding agents |
CA2899353A1 (en) | 2013-02-04 | 2014-08-07 | Oncomed Pharmaceuticals, Inc. | Methods and monitoring of treatment with a wnt pathway inhibitor |
US9168300B2 (en) | 2013-03-14 | 2015-10-27 | Oncomed Pharmaceuticals, Inc. | MET-binding agents and uses thereof |
JP2016532717A (ja) * | 2013-09-27 | 2016-10-20 | ヴァクシノゲン インターナショナル パートナーズ, エルピーVaccinogen International Partners, Lp | 自己腫瘍ワクチン及び方法 |
MX2017005707A (es) | 2014-11-05 | 2017-08-21 | Memorial Sloan Kettering Cancer Center | Metodos para seleccionar una linea de celulas t y el donador de la misma para terapia celular adoptiva. |
WO2016145292A1 (en) * | 2015-03-12 | 2016-09-15 | University Of Iowa Research Foundation | Vaccine, therapeutic composition and methods for treating or inhibiting cancer |
CN107921065A (zh) * | 2015-06-26 | 2018-04-17 | 纪念斯隆-凯特林癌症中心 | 通过t细胞疗法治疗cmv视网膜炎的方法 |
US10166255B2 (en) | 2015-07-31 | 2019-01-01 | Regents Of The University Of Minnesota | Intracellular genomic transplant and methods of therapy |
CN109068658A (zh) | 2015-11-18 | 2018-12-21 | 杜克大学 | 用于治疗癌症的肿瘤浸润淋巴细胞 |
JP7181862B2 (ja) | 2016-10-18 | 2022-12-01 | リージェンツ オブ ザ ユニバーシティ オブ ミネソタ | 腫瘍浸潤リンパ球および治療の方法 |
WO2018138682A1 (en) | 2017-01-26 | 2018-08-02 | Immune Therapeutics | Methods and compositions useful for treating cancer |
EP3645021A4 (en) | 2017-06-30 | 2021-04-21 | Intima Bioscience, Inc. | ADENO-ASSOCIATED VIRAL VECTORS FOR GENE THERAPY |
KR102256337B1 (ko) * | 2017-10-17 | 2021-05-26 | (주)노터스생명과학 | 조직이식을 위한 세포배양액을 포함하는 면역억제제 |
US11446329B2 (en) | 2017-11-01 | 2022-09-20 | Restem Llc | Natural killer cell adoptive transfer therapy for the elimination of senescent PBMCs, reduction of inflammatory cytokines and treatment of IBS |
IL259392A (en) | 2018-05-15 | 2018-08-01 | Yeda Res & Dev | Vaccination with cancer neo-antigens |
FR3082730B1 (fr) * | 2018-06-21 | 2022-04-22 | Med Inn Pharma | Methode de resolution de l'inflammation pro-tumorale a l'aide d'une preparation pharmaceutique |
WO2023196232A1 (en) * | 2022-04-04 | 2023-10-12 | University Of Florida Research Foundation, Inc. | Method of characterizing tumors |
CN114984199A (zh) * | 2022-04-19 | 2022-09-02 | 苏州尔生生物医药有限公司 | 一种基于癌症特异性t细胞的细胞系统、淋巴细胞药物及其应用 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5192537A (en) | 1984-03-30 | 1993-03-09 | Cellcor Inc. | Method of treating renal cell carcinoma using activated mononuclear cells, renal tumor antigen and cimetidine |
US4828991A (en) | 1984-01-31 | 1989-05-09 | Akzo N.V. | Tumor specific monoclonal antibodies |
JP2639835B2 (ja) * | 1988-11-30 | 1997-08-13 | 有限会社ジオリサーチ | 免疫記憶細胞懸濁液の調製方法 |
US5229115A (en) * | 1990-07-26 | 1993-07-20 | Immunex Corporation | Adoptive immunotherapy with interleukin-7 |
JPH06121672A (ja) * | 1992-10-13 | 1994-05-06 | Cellcor Inc | 免疫反応性細胞の製造 |
US5820872A (en) * | 1992-11-18 | 1998-10-13 | Yale University | Methods and compositions for improving the effectiveness of X-irradiation therapy for the treatment of an internal solid tumor |
EP0688223A4 (en) | 1993-03-12 | 1998-05-13 | Cellcor Inc | TITRATION METHOD -i (IN VITRO) FOR MEASURING THE DEGREE OF ACTIVATION OF IMMUNE CELLS |
EP0734440A1 (en) | 1993-12-14 | 1996-10-02 | Yajun Guo | Tumor cell fusions and methods for use of such tumor cell fusions |
US5759535A (en) | 1994-05-13 | 1998-06-02 | Research Corporation Technologies, Inc. | Immunotherapeutic strategies for the treatment of cancer |
CA2192655A1 (en) * | 1994-06-14 | 1995-12-21 | Edgar G. Engleman | Methods for in vivo t cell activation by antigen-pulsed dendritic cells |
DE4431401A1 (de) | 1994-08-24 | 1996-02-29 | Max Delbrueck Centrum | Lebendvakzine gegen Tumorerkrankungen |
KR19980703072A (ko) * | 1995-03-17 | 1998-09-05 | 스티븐슨 린다 에스 | 종양의 치료방법 |
US6277368B1 (en) * | 1996-07-25 | 2001-08-21 | The Regents Of The University Of California | Cancer immunotherapy using autologous tumor cells combined with cells expressing a membrane cytokine |
-
1997
- 1997-10-10 EP EP97910999A patent/EP0930887B1/en not_active Expired - Lifetime
- 1997-10-10 KR KR1019990703176A patent/KR20000049096A/ko not_active Application Discontinuation
- 1997-10-10 JP JP51780398A patent/JP2001509135A/ja not_active Ceased
- 1997-10-10 AU AU48242/97A patent/AU743855B2/en not_active Ceased
- 1997-10-10 AT AT97910999T patent/ATE229810T1/de not_active IP Right Cessation
- 1997-10-10 US US08/948,939 patent/US6207147B1/en not_active Expired - Lifetime
- 1997-10-10 DE DE69718029T patent/DE69718029T2/de not_active Expired - Lifetime
- 1997-10-10 WO PCT/US1997/018718 patent/WO1998016238A2/en active IP Right Grant
- 1997-10-10 CN CN97199908A patent/CN1237909A/zh active Pending
- 1997-10-10 BR BR9712988-7A patent/BR9712988A/pt not_active Application Discontinuation
- 1997-10-10 CA CA002267157A patent/CA2267157C/en not_active Expired - Fee Related
- 1997-10-13 AR ARP970104701A patent/AR004445A1/es not_active Application Discontinuation
-
1999
- 1999-04-09 NO NO991691A patent/NO991691L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
DE69718029T2 (de) | 2003-10-16 |
US6207147B1 (en) | 2001-03-27 |
CA2267157A1 (en) | 1998-04-23 |
AU4824297A (en) | 1998-05-11 |
NO991691D0 (no) | 1999-04-09 |
NO991691L (no) | 1999-06-09 |
AR004445A1 (es) | 1998-12-16 |
ATE229810T1 (de) | 2003-01-15 |
KR20000049096A (ko) | 2000-07-25 |
JP2001509135A (ja) | 2001-07-10 |
EP0930887A2 (en) | 1999-07-28 |
WO1998016238A3 (en) | 1998-09-11 |
DE69718029D1 (de) | 2003-01-30 |
CA2267157C (en) | 2005-05-31 |
EP0930887B1 (en) | 2002-12-18 |
CN1237909A (zh) | 1999-12-08 |
AU743855B2 (en) | 2002-02-07 |
WO1998016238A2 (en) | 1998-04-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR9712988A (pt) | Imunoterapia do câncer usando células tumorais combinadas com mistura de linfócitos | |
Marshall et al. | Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti–carcinoembryonic antigen immune responses | |
Hui et al. | Phase I study of immunotherapy of cutaneous metastases of human carcinoma using allogeneic and xenogeneic MHC DNA–liposome complexes | |
EP0789574A4 (en) | METHOD AND DEVICES FOR IMMUNIZING A HOST AGAINST TUMOR ASSOCIATED ANTIGENS BY ADMINISTRATING NAKED POLYNUCLEOTIDES CODING TUMOR ASSOCIATED ANTIGEN PEPTIDES | |
BR0113491A (pt) | Polinucleotìdeo e polipeptìdeo isolados, vetor de expressão, célula hospedeira, proteìna de fusão, métodos para estimular e/ou expandir células t especìficas para uma protéina de tumor, para estimular uma resposta imune em um paciente, para o tratamento de um câncer em um paciente e para inibir o desenvolvimento de um câncer em um paciente, população de célula t isolada, composição, e, uso de um componente. | |
ATE389712T1 (de) | Krebs immuntherapie mit semi-allogenen zellen | |
BR0112542A (pt) | Composições e métodos papa a terapia e a diagnose de câncer ovariano | |
ES2826480T3 (es) | Métodos para predecir la utilidad de neoantígenos para inmunoterapia | |
BR9916207A (pt) | Composições e métodos para terapia e diagnósticode câncer ovariano | |
Triozzi et al. | Phase I study of a plasmid DNA vaccine encoding MART-1 in patients with resected melanoma at risk for relapse | |
Lynch et al. | In vivo evaluation of the effects of interleukins 2, 4 and 7 on enhancing the immunotherapeutic efficacy of anti‐tumor cytotoxic T lymphocytes | |
Morton et al. | Active specific immunotherapy in malignant melanoma | |
US20100092499A1 (en) | Alpha Thymosin Peptides as Cancer Vaccine Adjuvants | |
Hage et al. | TAP expression level in tumor cells defines the nature and processing of MHC class I peptides for recognition by tumor‐specific cytotoxic T lymphocytes | |
WO2003033520A3 (en) | Anticancer vaccine and diganostic methods and reagents | |
Correale et al. | Tumour-associated antigen (TAA)-specific cytotoxic T cell (CTL) response in vitro and in a mouse model, induced by TAA-plasmids delivered by influenza virosomes | |
thor Straten et al. | T-cell clonotypes in cancer | |
Delman et al. | Efficacy of multiagent herpes simplex virus amplicon-mediated immunotherapy as adjuvant treatment for experimental hepatic cancer | |
Mellstedt et al. | Ga733/EpCAM as a target for passive and active specific immunotherapy in patients with colorectal carcinoma | |
Baltz | Vaccines in the treatment of cancer | |
NO930798L (no) | Fremgangsmaate og middel mot tumorer | |
DE60130634D1 (de) | Identifizierung von antigenen peptiden durch zytotoxische t-lymphozyten aktiviert von dendritischen zellhybriden | |
DeBruyne et al. | Direct transfer of a foreign MHC gene into human melanoma alters T cell receptor Vβ usage by tumor-infiltrating lymphocytes | |
Pazdur et al. | Vaccines: an innovative approach to treating cancer | |
CN1239431A (zh) | 致免疫的tlp组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA10 | Dismissal: dismissal - article 33 of industrial property law | ||
B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] | ||
B15K | Others concerning applications: alteration of classification |
Ipc: A61K 35/17 (2015.01), A61K 35/13 (2015.0 |